Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Big point is

<< Previous

Bullboard Posts

Next >>

Post by SimonSaysLueson Apr 14, 2024 2:20am

529 Views

Post# 35987987

Big point is

None of the science matters at this juncture. Ate owes 33 mil to Nuance. There is no appeal process. End story. Nuance is a big company. Has the best lawyers. Is found to be right by a court Nuance will be ruthless.

And if all this has Stemmed from ATE not communicating effectively with Health Canada, than it's Ate's own ineptness that destroyed itself

<< Previous

Bullboard Posts

Next >>

Payfare stock nosedives after losing biggest client, DoorDash